By proceeding, you agree to our Terms of Use and Privacy Policy.
Join us at the 14th World ADC San Diego conference, where the revolutionary field of antibody-drug conjugates (ADCs) continues to make remarkable strides in the oncology landscape. In the year 2023, the ADC renaissance reaches new heights with the eagerly anticipated approval of ImmunoGen's ELAHERE, marking the ninth ADC to receive regulatory clearance in just three years. This groundbreaking achievement brings renewed hope as ELAHERE becomes the first ADC approved for platinum-resistant ovarian cancer, extending the potential of ADC treatments beyond breast cancer.No matter if you are new to the ADC space or an experienced ADC guru, the 14th World ADC San Diego event is tailor-made for you. Covering every stage of ADC development, from early discovery to late-stage manufacturing and regulatory challenges, this conference aims to optimize the therapeutic window of your ADC and accelerate their transformation into life-changing, frontline therapies for oncology patients.Prepare to be part of the largest gathering of ADC experts ever assembled, with over 800 world-leading attendees from esteemed organizations such as Daiichi Sankyo, ImmunoGen, AbbVie, Gilead Sciences, and Seagen. This event promises an unparalleled convergence of the ADC community, fostering invaluable networking opportunities and collaborations among the brightest minds in the field.Don't miss your chance to be at the forefront of the ADC revolution. Join us at the 14th World ADC San Diego conference and be inspired by the latest breakthroughs, emerging trends, and cutting-edge research that will shape the future of ADCs in oncology. Together, let's propel ADCs towards their full potential and make a profound impact on the lives of cancer patients worldwide.
Stay ahead in antibody-drug conjugates and gain valuable insights from industry leaders.
Discover novel ADC platforms, innovative drug designs, and advanced conjugation techniques through scientific discussions to enhance your ADC development process.
Engage in meaningful networking opportunities with key stakeholders, including researchers, biotech companies, CROs, and regulatory experts.
Be motivated by success stories and future perspectives to drive innovation and make a difference in the development of targeted cancer therapies.
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
Sartorius is a leading international partner of life science research and the biopharmaceutical industry.
Absci is the drug and target discovery company harnessing deep learning and synthetic biology to expand the therapeutic potential of proteins.
Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data.
Founded in 2013, Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development.
SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to find answers to the complex analytical challenges they face.
Make faster and better informed drug development decisions In partnership with the world’s leading drug development experts to help you keep up with the pace of preclinical and clinical research developments.
Abzena is a life science group with headquarters in the UK, and chemistry and manufacturing sites in the US.
Founded in 1974, Trinity Consultants helps organizations overcome complex, mission-critical challenges in EHS, engineering, and science through expertise in consulting, technology, training, and staffing.
Synaffix BV is a biotech company that has established a proprietary, clinical-stage antibody-drug conjugate (ADC) technology platform that delivers best-in-class ADCs (safety and efficacy). Our platform is commercially validated by well over $1.
NJ Biopharmaceuticals LLC (d/b/a NJ Bio) is a CRO that provides integrated chemistry and biology services to clients from the biotech and pharma sectors.
At Lonza, we enable #AHealthierWorld by supporting our healthcare customers on the path to commercialization.
Ardena is a pharmaceutical CDMO that guides companies through the drug discovery and development process to help create effective and compliant drug substance and products for clinical trials.
“Every drug can be made and every disease can be treated” by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry.
Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India providing comprehensive development, cGMP manufacturing, and aseptic fill finish services f
BSP Pharmaceuticals S.p. A. is focused on the development and manufacturing of anticancer drugs with high potency and cytotoxitc characteristics for the Pharmaceuticals Industry. BSP has been at the forefront in the fight agains cancer since 2006.
CARBOGEN AMCIS leverages its world-class chemistry skills to provide seamless drug substance, drug products development and commercialization services for leading pharmaceutical and biopharmaceutical companies.
Heraeus, the technology group headquartered in Hanau, Germany, is a leading international family-owned portfolio company. The company’s roots go back to a family pharmacy started in 1660.
LegoChem Biosciences, Inc.
Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle.
Formed in 2015, PROVEO is now a Division of Cerbios- Pharma SA focused on complete supply chain solution for Antibody Drug Conjugates (ADCs).
Antibody Screening - Unravelling the full potential of entire immune repertoires (millions of B cells) VERAXA´s unique platform can combine the assessment of antibody binding with its functional capabilities in 1 single screening step, using a propri
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.